Primary Prevention ICD French Registry

Observatoire Multicentrique Français Des Porteurs de Défibrillateur Automatique Implantable en Prévention Primaire (Cardiopathie Ischémique ou Cardiomyopathie Dilatée)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01992458

Acronym

DAI-PP

Enrollment

5576

Registered

2013-11-25

Start date

2012-01-31

Completion date

2013-11-30

Last updated

2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of Primary Prevention ICD in Real Life

Keywords

implantable cardioverter defibrillator, death, shock, mortality, complication, sudden death

Brief summary

The indication of implantable cardioverter defibrillator (ICD) therapy for primary prevention of sudden cardiac death has been introduced later in France than in other parts of the World. Overall, we aimed to assess the risk-benefit ratio of this strategy over a 10 year period.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Coronary artery disease or dilated cardiomyopathy with low ejection fraction implanted with an ICD in the setting of primary prevention (criteria at the discretion of the physician)

Exclusion criteria

* Setting of secondary prevention * Other cardiopathies such as congenital, channelopathies, valvulopathies

Design outcomes

Primary

Measure	Time frame
Incidences of Appropriate Therapies (ATP and Shocks) and ICD-Related Complications	3-year

Secondary

Measure	Time frame
Cause-of-Death Analysis	3-year

Countries

France

Outcome results